Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cartesian Therapeutics, Inc. - Common Stock (NQ: RNAC )

12.05 +0.42 (+3.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 50,389
Open 11.63
Bid (Size) 12.00 (1)
Ask (Size) 12.06 (2)
Prev. Close 11.63
Today's Range 11.63 - 12.18
52wk Range 8.850 - 41.87
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert
U.S. stock futures were volatile on Wednesday after the equities reversed gains on Tuesday following Donald Trump's 104% tariff on China. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Why Venus Concept Shares Are Trading Higher By Over 200%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-28.82%
-28.82%
1 Month
-24.40%
-24.40%
3 Month
-36.78%
-36.78%
6 Month
-45.67%
-45.67%
1 Year
-41.48%
-41.48%

More News

Read More
Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients
Via Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Via Investor's Business Daily
RNAC Stock Earnings: Cartesian Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Cartesian Therapeutics Plummets On 'Watershed Moment' For CAR-T Drugs
Via Investor's Business Daily
Cartesian's Autoimmune Disorder Candidate Hits Primary Goal In Mid-Stage Study, Announces Equity Raise Of $130M
Via Benzinga
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Cartesian Therapeutics Announces New Employment Inducement Grants
From Cartesian Therapeutics, Inc.
Via Business Wire
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
From Cartesian Therapeutics, Inc.
Via Business Wire
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Via Benzinga
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Cartesian Therapeutics, Inc.
Via Business Wire
Cartesian Therapeutics Announces New Employment Inducement Grants
From Cartesian Therapeutics
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
LivePerson And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
SolarEdge Layoffs 2024: What to Know About the Latest SEDG Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.